PMIScience

Better decisions are only possible when people have clear and scientifically accurate facts that cut through confusion. Because misconceptions about smoke-free products persist, we’re committed to strengthening transparency by openly sharing key scientific facts and figures behind our progress.

Behind our smoke-free vision is a diverse team of over 1,400 specialists dedicated to improving the way science serves society. At PMI Science, our community brings together a broad range of disciplines and collective expertise to advance our scientific research and drive meaningful innovation 👇

Misinformation can obscure scientific truth, creating false narratives that confuse the public and hinder the innovation needed for a better future. That’s why we continue to share our research findings and studies openly through resources like our PMI Science Booklet and Leaflet, reinforcing our commitment to transparency and integrity.

Through sharing our research openly, publishing peer-reviewed research, and continuously investing in innovation, we’re committed to turning data into dialogue and evidence into trust. This is what measurable progress looks like 👉 spr.ly/6017hdlWX

We’re proud of our extensive portfolio of patents, which reflects our ongoing investment in creating, scientifically substantiating, and commercializing smoke‑free products that offer adult smokers better alternatives to cigarettes. #SmokeFreeFuture #ResearchAndDevelopment

@_Othman_Najib Our smoke‑free portfolio includes a range of product types offered at different price points, so adult smokers who don’t quit have options that better fit their preferences and needs.

@PMIScience However, for me, it might be "right" to provide other affordable alternatives that take into account the needs of adult smokers with limited income.

Behavioral science helps us understand what motivates change. PMI’s studies on perception and behavior show that our smoke-free products are perceived to have a lower risk of harm compared with cigarettes and can support tobacco harm reduction efforts. Read more about our perception and behavior research in Issue 21 of our Scientific Update Magazine ➡️ spr.ly/6016C9zQY #PerceptionBehavior #HarmReduction #ScienceCommunication

10 years of postmarket safety surveillance data. What have we learned? The 22nd issue of the Scientific Update showcases PMI’s commitment to monitor product safety after market release, highlighting the work of our safety surveillance team and sharing findings from the robust postmarket safety surveillance system established at PMI. Swipe to explore 👇

Sweden’s long-standing use of oral smokeless alternatives, like snus and more recently nicotine pouches, has contributed to the lowest smoking rate in Europe. This shift offers valuable insights for other countries exploring ways to reduce cigarette use. Discover the science and technology behind nicotine pouches here 👉 spr.ly/6010h3a2K #SwedishExperience #NicotinePouches #SmokeFreeFuture

Raising cigarette prices can help reduce tobacco harm. Data shows that higher prices can help cut smoking rates and, when paired with progressive, risk-proportionate taxation of smoke-free products, can encourage adult smokers who don’t quit to switch to better alternatives. Effective pricing works best alongside strong enforcement to prevent illicit trade.

@PMIScience 🤔 Can pricing traditional cigarettes contribute to supporting efforts to reduce tobacco harm?

What drives adult smokers to consider switching to smoke-free alternatives? We are using science to find the answers. Explore the full findings in our PMI Science Booklet: spr.ly/6017hyOC5 #PerceptionBehavior #RiskPerception #SmokeFreeAlternatives

Our goal is simple: to accelerate the end of smoking through science‑based innovation and transparent scientific communication. When science is open, progress is faster. Here’s more on some of the ways we make our research accessible, and encourage dialogue across the global scientific community👇

Majority of the toxicants in cigarette smoke originate from burning tobacco at high temperatures. By heating tobacco at low temperatures instead of burning it, our leading heated tobacco product emits an aerosol that contains significantly fewer and lower levels of toxicants compared with cigarette smoke. Find out more about the difference between smoke and aerosol 👉 spr.ly/6013C4ShL #HeatedTobacco #SmokeVsAerosol

Dr. Fischer, Manager of Regulatory Consumer Research at PMI, leads postmarket studies on the role of heated tobacco products (HTPs) in harm reduction. Her research, including a 6-year study in Japan, explores how millions of adult smokers have transitioned from cigarettes to HTPs—contributing to a continued decline in smoking prevalence. For her interview in full to explore her research on tobacco harm reduction 👉 spr.ly/6016C9Mbe

At PMI, proactive monitoring of the safety profile of our smoke-free products and strict regulatory compliance is paramount. Our robust postmarket safety surveillance framework ensures that this is upheld throughout the entire product lifecycle. More on our approach 👉 spr.ly/6012C3mrI

Harm reduction focuses on reducing risks rather than eliminating behaviors entirely. In the case of smoking, harm reduction involves complementing traditional tobacco control measures with approaches that could help accelerate the decline in smoking prevalence and, as a result, deliver potential benefits for public health. In what other ways can harm reduction be applied? Test yourself👇

Clinical research is a cornerstone of our smoke-free product assessment. At Philip Morris International, we conduct clinical studies to evaluate the potential of our smoke-free products to reduce exposure to harmful chemicals and reduce the risk of harm as compared with cigarettes. Find out more about our clinical studies here ➡️ spr.ly/60137p505 #ClinicalStudies #ClinicalResearch #ClinicalResults

At Philip Morris International, we set ourselves the highest standards in our science and research practices. This is why we follow pharmaceutical industry standards to scientifically substantiate our smoke-free products. This includes internationally recognized guidelines for Good Clinical Practice issued by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use. These guidelines require that our researchers perform their work ethically, use scientifically sound methods, and that our data is traceable and credible. Learn more about how we conduct our smoke-free product research and explore the results of our studies here ➡️ spr.ly/60167rArC #StudyResults #ScientificMethod #PharmaceuticalStandard #ClinicalPractice

Substances used to measure the effect of exposure to a harmful chemical on the human body are known as biomarkers of potential harm (BoPH). Our clinical studies on biomarkers demonstrate that adult smokers who switch completely to our leading heated tobacco product have favorable differences in BoPH levels from those of current smokers and similar to those of former smokers. Find more information here ➡️ spr.ly/60117O1DT #ClinicalStudies #Biomarkers #ClinicalResearch

Why do we share our research results openly? Sharing our research through peer-reviewed publications, conference presentations, and on PMIScience.com builds transparency and trust in our science and fosters informed dialogue on the potential benefits of smoke-free products on tobacco harm reduction. #Transparency #ScientificPublications #OpenScience